Key terms
About IART
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IART news
Apr 22
9:25am ET
Jefferies Sticks to Their Buy Rating for Integra Lifesciences (IART)
Apr 03
9:54am ET
UPS upgraded, PepsiCo downgraded: Wall Street’s top analyst calls
Apr 03
5:43am ET
Integra LifeSciences upgraded to Neutral from Sell at Citi
Mar 11
8:33am ET
Integra LifeSciences launches MicroMatrix Flex
Feb 29
7:41am ET
Integra LifeSciences price target lowered to $42 from $45 at BofA
Feb 29
7:22am ET
Truist Financial Sticks to Their Hold Rating for Integra Lifesciences (IART)
Feb 29
7:18am ET
Integra LifeSciences price target lowered to $49 from $55 at JMP Securities
Feb 29
6:52am ET
BTIG Sticks to Its Hold Rating for Integra Lifesciences (IART)
Feb 29
6:14am ET
Integra LifeSciences price target lowered to $45 from $49 at Wells Fargo
Feb 29
5:39am ET
Buy Rating on Integra Lifesciences Amidst Recovery and Growth Prospects
Feb 29
5:28am ET
Integra Lifesciences: Sell Rating Justified by Underwhelming Financials and Leadership Concerns
Feb 29
12:40am ET
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Integra Lifesciences (IART)
Feb 28
6:32am ET
Integra Lifesciences Announces CEO Transition and New Executive Chairman
Feb 28
6:09am ET
Integra LifeSciences CEO Jan De Witte to retire by the end of 2024
Feb 28
6:08am ET
Integra LifeSciences sees Q1 adjusted EPS 53c-57c, consensus 74c
Feb 28
6:07am ET
Integra LifeSciences sees FY24 adjusted EPS $3.15-$3.25, consensus $3.44
Feb 28
6:05am ET
Integra LifeSciences reports Q4 adjusted EPS 89c, consensus 90c
Feb 21
6:50pm ET
Analysts Are Bullish on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Integra Lifesciences (IART)
Feb 06
8:07am ET
Integra Lifesciences: A Strong Buy on FDA Approval and Re-launch Optimism
Feb 06
5:39am ET
Integra Lifesciences (IART) Receives Buy Rating Following FDA Approval of CereLink Monitors
IART Financials
Key terms
Ad Feedback
IART Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IART Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range